The anti-PD-1/PD-L1 antibodies serve as potent immune checkpoint inhibitors (ICIs) are designed to block the activity of immune checkpoint proteins and promote T cell activation to achieve anti-tumor immune effects. This evidence concerns the gene CD274 and neoplasm.